Ceres Brain Therapeutics

Its clinical research also covers pharmacokinetics, along with safety and tolerability assessment for investigational neurological treatments. These areas are central to understanding how candidate therapies behave in the body and how they are received by participants.

• Pharmacokinetic Profiling
• Safety Evaluation
• Tolerability Assessment

The sponsor’s interest in these domains aligns with the development of new pharmaceutical options for brain disorders.

Ceres Brain Therapeutics funds studies involving healthy male subjects, supporting early clinical investigation of candidate therapies before broader patient-focused development. This area is relevant to characterizing how experimental treatments are handled in the body under controlled conditions.

• Healthy Volunteer Studies
• Early Clinical Development
• Human Translational Research

Such research contributes to the clinical understanding of new approaches intended for neurological treatment.

The sponsor shows interest in intranasal administration as a route for delivering investigational compounds, a strategy particularly relevant to therapies targeting the brain and nervous system. This therapeutic domain supports development work in non-oral delivery for neurological applications.

• Intranasal Drug Delivery
• Neurological Delivery Platforms
• Brain-Access Therapeutics

Its research activity is concentrated in France, with active clinical involvement in a single ongoing study.